Susann Mischke, NP
Acute Care · Santa Rosa, CANPI 1366067449
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,547 of the $6,594 with a category attached, or 68.9%. 26 manufacturers reported payments, led by Medtronic at 41.7% of the total. Reporting peaked in 2022 at $2,855 and has fallen 65.8% since, to $977 in 2025. Among acute care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 140 payments — averaging $47.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Edwards Lifesciences$1K
- Merck$396
- Boston Scientific$336
- Actelion Pharmaceuticals US, Inc.$300
- Boehringer Ingelheim$265
- plus $1K from 20 others
What the payments were for
- Travel & lodging$2,03431%
- Food & beverage$4,54769%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 28 | $2,751 |
| Edwards Lifesciences | 13 | $1,192 |
| Merck | 16 | $396 |
| Boston Scientific | 4 | $336 |
| Actelion Pharmaceuticals US, Inc. | 8 | $300 |
| Boehringer Ingelheim | 11 | $265 |
| Heartflow, Inc. | 2 | $220 |
| Novartis | 9 | $200 |
| Amgen | 6 | $135 |
| AstraZeneca | 7 | $116 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $114 |
| Esperion Therapeutics, Inc. | 4 | $100 |
| E.r. Squibb & Sons, L.L.C. | 5 | $89 |
| United Therapeutics Corporation | 3 | $79 |
| Bayer | 2 | $54 |
| Lexicon Pharmaceuticals, Inc. | 2 | $38 |
| Johnson & Johnson | 2 | $37 |
| Pfizer | 1 | $25 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Abiomed | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Bridgebio Pharma, Inc. | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$1,250
- CoreValve Evolut$640
- Edwards SAPIEN 3 Transcatheter Heart Valve$530
- Micra$375
- FFRct$185
- WATCHMAN Access System$150
- SAPIEN 3 Ultra RESILIA$140
- UPTRAVI$118
- OPSUMIT$118
How this compares
$6,594 in reported general payments places this provider in the 95th percentile of 1,153 acute care providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 170 | $221,640 |
| EntrestoSacubitril/Valsartan | 73 | $74,289 |
| XareltoRivaroxaban | 37 | $51,625 |
| JardianceEmpagliflozin | 33 | $42,509 |
| Clonidine | 11 | $2,624 |
| Atorvastatin Calcium | 154 | $1,788 |
| Metoprolol Succinate | 123 | $1,689 |
| Amiodarone Hcl | 44 | $1,395 |
| Valsartan | 39 | $1,345 |
| Ezetimibe | 37 | $1,286 |
| Rosuvastatin Calcium | 59 | $1,149 |
| Furosemide | 159 | $896 |
| Potassium Chloride | 69 | $892 |
| Amlodipine Besylate | 85 | $870 |
| Diltiazem 24hr ErDiltiazem Hcl | 11 | $760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $25 | $221,640170 claims |
| NovartisEntresto | $200 | $74,28973 claims |
| Johnson & JohnsonXarelto | $37 | $51,62537 claims |
| Boehringer IngelheimJardiance | $265 | $42,50933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,153 acute care providers in California.
Other acute care in Santa Rosa
- Jayson SantiagoSanta Rosa$9K
- Leslie PetersenCamarillo$370K
- Joyce KhremianSan Dimas$73K
- Eleanor VierraSacramento$64K
- Frances DyLos Angeles$57K
- Savannah HarrisVentura$56K
- Kori Ann JohnstonLos Angeles$42K
- Caroline KwongOrange$42K
- Gregory KnutzenColton$41K
- Sunita BoparaiLos Angeles$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.